Close Menu

Lung Cancer

News and reporting on lung cancer.

The company will use proceeds to support commercialization of its lung cancer liquid biopsy test, and to fund studies to cement reimbursement and adoption.

In PNAS this week: sepsis-related copy number changes, three-dimensional leaf transcriptomes of plants grow in dark or in light-dark cycles, and more.

In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.

In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.

The test showed 90 percent sensitivity and 75 percent specificity in a 250-patient blinded study, even without the addition of clinical risk information.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.

Researchers traced genomic, epigenomic, and expression features in lung carcinoma in situ cases that regressed or progressed to invasive lung squamous cell carcinomas.

In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.

Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.

The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.

Pages

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.